top of page
Decoding neurological disease. Building medicines with precision.
CELLTIUM is developing precision therapies for CMT1A and related inherited peripheral neuropathies. By uniting deep disease biology with our proprietary PRECISION™ platform, we are accelerating the translation of discovery into truly disease‑modifying therapies.
A New Model for Neurotherapeutics
At the core of our approach is an integrated discovery engine that combines quantitative phenotyping, multimodal data, and AI/ML. This framework supports target identification, lead optimization, and data‑driven decision‑making from the outset.
Targeting Core Disease Biology
We are advancing a precision pipeline of mechanistically distinct small‑molecule programs designed to address the root causes of peripheral neuropathies. Rather than managing symptoms alone, our goal is to restore nerve function and meaningfully change the course of disease.
Partner With Us
We welcome strategic collaborations with investors and biopharma partners to advance our lead CMT1A program into the clinic and to extend our platform across additional indications in neurology and rare disease.
bottom of page